Lilly(Eli) & Company
NYSE: LLY
$887.16
+$1.61 (+0.2%)
Closing Price on October 4, 2024
LLY Stock Chart and Intraday Price
LLY Stock Data
| Asset Type | Stock |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 743,142.26M USD |
| Shares Outstanding | 950,164,000 |
LLY Articles
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and currently trading at $885.25. The company has been around since 1876 and the...
Published:
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
Published:
The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we need it, to everyday pain remediation or allergy medications, big pharma...
Published:
Diversification is key in today’s investing world. Exchange-traded funds, or ETFs, offer a convenient and affordable way to achieve this. Think of them as baskets filled with a variety of stocks....
Published:
247 Wall St. Key Insights QQQ offers higher growth potential but comes with greater risk due to its reliance on tech stocks. VOO provides broad market exposure with lower risk and steady growth. ...
Published:
Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which I’m going to dive into with a few of these picks. Whether we’re...
Published:
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Published:
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Published:
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
Published:
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and...
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Published:
Unless you have been living under the rock, you’d have heard of Nvidia’s (NASDAQ: NVDA) success story. All investors want a bite of this big business and those who missed out are now trying to...
Published:
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published: